About Us
Submissions
Advertising
SIGN IN
|
SUBSCRIBE
ISSUE
CURRENT
ARCHIVE
SUPPLEMENTS
JADPRO LIVE
2020
JADPRO Live 2019 Activities
JADPRO Live 2018 Activities
CE
QUICK TIPS
SPECIAL CONTENT
Benign Hematology Updates
Roundtable Series: Bone Health
Expert Conversations
Clinical Case Series
Roundtable Series: Multiple Myeloma
Cardio-Oncology Updates
MPN Resource Center
APSHO Educator Modules
HIGHLIGHTS
PODCAST
Learn more on this topic:
Overview of Immunotherapy
What are the mechanisms of action and adverse effects of these agents?
R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA
Related Material
Is programmed cell death ligand 1 (PD-L1) testing necessary?
When should you image patients to assess response to immunotherapy?
Why is pseudo-progression an important issue in patients on immune checkpoint inhibitors?
How do responses to immune checkpoint inhibitors differ from responses to chemotherapy?
What cancers are most likely to respond to immunotherapy?
How do you educate patients about the timing of early and latent side effects?
Bot trap - Don't go here
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our
Privacy Policy
to learn more.